MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1158/1078-0432.ccr-23-0475

Медицинская библиотека · Clinical cancer research : an official journal of the American Association for Cancer Research · 2024

A Phase II Trial of the CD40 Agonistic Antibody Sotigalimab (APX005M) in Combination with Nivolumab in Subjects with Metastatic Melanoma with Confirmed Disease Progression on Anti-PD-1 Therapy.

Weiss Sarah A, Sznol Mario, Shaheen Montaser, Berciano-Guerrero Miguel-Ángel, Couselo Eva Muñoz, Rodríguez-Abreu Delvys, Boni Valentina, Schuchter Lynn M, Gonzalez-Cao Maria, Arance Ana, Wei Wei, Ganti Apar Kishor, Hauke Ralph J, Berrocal Alfonso, Iannotti Nicholas O, Hsu Frank J, Kluger Harriet M

Клиническое исследование II фазыМногоцентровое исследованиеСтатьяПоддержка NIH: внешняя программаПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

PURPOSE: Disease progression during or after anti-PD-1-based treatment is common in advanced melanoma. Sotigalimab is a CD40 agonist antibody with a unique epitope specificity and Fc receptor binding profile optimized for activation of CD40-expressing antigen-presenting cells. Preclinical data indicated that CD40 agonists combined with anti-PD1 could overcome resistance to anti-PD-1.

PATIENTS AND

METHODS

We conducted a multicenter, open-label, phase II trial to evaluate the combination of sotigalimab 0.3 mg/kg and nivolumab 360 mg every 3 weeks in patients with advanced melanoma following confirmed disease progression on a PD-1 inhibitor. The primary objective was to determine the objective response rate (ORR).

RESULTS

Thirty-eight subjects were enrolled and evaluable for safety. Thirty-three were evaluable for activity. Five confirmed partial responses (PR) were observed for an ORR of 15%. Two PRs are ongoing at 45.9+ and 26+ months, whereas the other three responders relapsed at 41.1, 18.7, and 18.4 months. The median duration of response was at least 26 months. Two additional patients had stable disease for >6 months. Thirty-four patients (89%) experienced at least one adverse event (AE), and 13% experienced a grade 3 AE related to sotigalimab. The most common AEs were pyrexia, chills, nausea, fatigue, pruritus, elevated liver function, rash, vomiting, headache, arthralgia, asthenia, myalgia, and diarrhea. There were no treatment-related SAEs, deaths, or discontinuation of sotigalimab due to AEs.

CONCLUSIONS

Sotigalimab plus nivolumab had a favorable safety profile consistent with the toxicity profiles of each agent. The combination resulted in durable and prolonged responses in a subset of patients with anti-PD-1-resistant melanoma, warranting further evaluation in this setting. See related commentary by Wu and Luke, p. 9.

Для цитирования: Weiss Sarah A, Sznol Mario, Shaheen Montaser, Berciano-Guerrero Miguel-Ángel, Couselo Eva Muñoz, Rodríguez-Abreu Delvys, Boni Valentina, Schuchter Lynn M, Gonzalez-Cao Maria, Arance Ana, Wei Wei, Ganti Apar Kishor, Hauke Ralph J, Berrocal Alfonso, Iannotti Nicholas O, Hsu Frank J, Kluger Harriet M. A Phase II Trial of the CD40 Agonistic Antibody Sotigalimab (APX005M) in Combination with Nivolumab in Subjects with Metastatic Melanoma with Confirmed Disease Progression on Anti-PD-1 Therapy.. Clinical cancer research : an official journal of the American Association for Cancer Research. 2024. DOI: 10.1158/1078-0432.ccr-23-0475.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.